Doctors expose: High drug prices not for R&D cost, but profiteering

Drug prices, especially of new and innovative drugs are high, supposedly to enable pharmaceutical companies to recoup the cost of drug discovery. A recent editorial by 100 Chronic Myeloid Leukemia (CML) experts from across the world has exposed how drug companies charge prices way above what is required to maintain healthy profits. Imatinib—priced $30,000 per yr to make “healthy profits”, says Novartis.

Read Full Story>>